Overview
Lobbying Costs
100,000€ - 199,999€
Financial year: Jan 2022 - Dec 2022
Lobbyists (Full time equivalent)
1.2 Fte (12)
Lobbyists with EP accreditation
0
High-level Commission meetings
1
Lobbying Costs over the years
-
Info
The Health Policy Partnership (HPP)
EU Transparency Register
223430420230-66 First registered on 08 Jan 2016
Goals / Remit
We are a specialist health policy consultancy. We create innovative policy initiatives and powerful evidence–based communications for organisations across the health spectrum. We provide a unique, seamless approach to help resolve the most complex issues facing our health care systems. We do this through rigorous research and expert synthesis of evidence, inter-sectoral collaboration, and powerful communications that act as the starting point for meaningful changes in policy and practice.
Main EU files targeted
Public health and healthcare policy, specific focus in cardiovascular disease, cancer, heart failure,rare diseases and respiratory issues.
Address
Head Office
The Health Policy Partnership 68-69 St Martin's Lane
London WC2N 4JS
UNITED KINGDOMEU Office
The Health Policy Partnership 68-69 St Martin's Lane
London WC2N 4JS
UNITED KINGDOMWebsite
-
People
Total lobbyists declared
12
Employment time Lobbyists 10% 12 Lobbyists (Full time equivalent)
1.2
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
Time provided above relates to HPP staff time dedicated to any formal engagement with MEPs, EU officials, or where there is policy activity directly involving or targeting EU institutions - i.e. it excludes general health policy activities where other audiences are our primary targets (e.g. national policy makers, academic experts, clinicians, health providers etc), and global activities.
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Professional consultancies
-
Networking
Affiliation
Heart Failure Policy Network - www.hfpolicynetwork.eu
(provide secretariat and lead project)Member organisations
None declared
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jan 2022 - Dec 2022
Lobbying costs for closed financial year
100,000€ - 199,999€
Major contributions in closed year
None declared
Intermediaries for closed year
None declaredIntermediaries for current year
None declaredClosed year Costs
100,000€ - 199,999€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
SPEAK UP FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
‘Speak Up’ is a multi-stakeholder coalition between Global Allergy & Airways Patient Platform (GAAPP), International Federation of Aging (IFA), COPD Foundation, International Coalition of Respiratory Nurses (ICRN), International Pharmaceutical Federation (FIP), in 2023 it received funding from AstraZeneca, Roche, Sanofi and Regeneron. All partners contributed time and expertise to the coalition activities. The coalition aims to raise awareness and understanding of chronic obstructive pulmonary disease (COPD) amongst policymakers and healthcare decision-makers by amplifying the voices of patients, the COPD community, and the public. HPP are supporting Speak Up on a new policy initiative that aimed to drive policy prioritisation for COPD and ultimately push COPD higher on policy agendas. As part of the ongoing activities, in October 2023, HPP organised a workshop gathering policymakers, experts in COPD, and other relevant stakeholders to examine current barriers to greater awareness and policy prioritisation of COPD and explore how to make messages about COPD resonate with policymakers. Whilst MEPS were invited to participate in the workshop, none were able to attend. In 2024, HPP will be developing a global ‘State of COPD’ policy report which will assess the current policy landscape in COPD in key countries/regions and outline essential areas for future policy action.
HEART FAILURE POLICY NETWORK (HFPN)
HPP acts as Secretariat for HFPN, a multidisciplinary group of experts from across Europe working with patients, health professionals and other stakeholders to lead significant policy changes that may improve the lives of people with heart failure (HF). The HFPN has ongoing relationships with several MEPs who donate their time for free to support (and act as Members of) the HFPN. In 2023, HFPN initiated the European Heart Failure Mission which aimed to secure political recognition and investment for HF from the EU. In October 2023, HFPN launched a Mission Statement (a call to action to the EU) at an event at the European Parliament. The event, hosted by Billy Kelleher MEP and gathering together 50 members of the heart failure community from across Europe, kicked off a multi-year campaign to drive heart failure to the top of the political agenda. The EU Mission activities are funded by AstraZeneca and Roche Diagnostics.
LUNG CANCER IN EUROPE: ACCELERATING OPPORTUNITIES TO IMPROVE SURVIVAL
In November 2023, HPP organised a webinar entitled ‘Lung cancer in Europe: accelerating opportunities to improve survival’. The online event was attended by patient advocates, clinicians and researchers to discuss priorities for improving the early detection and treatment of lung cancer in Europe. Penilla Gunther from the European Cancer Organisation spoke in her role as part of the EU Cancer Mission Board. This event was funded by Johnson & Johnson NCB an affiliate of Johnson & Johnson. The Health Policy Partnership was engaged by Johnson & Johnson to organise and develop the event on its behalf. The webinar and associated outputs were non-promotional and evidence based and are created by The Health Policy Partnership on behalf of Johnson & Johnson NCB.
WILSON'S DISEASE POLICY NETWORK
HPP runs the Secretariat for the Wilson’s Disease Policy Network, in collaboration with its multi-stakeholder Steering Committee. All outputs are non-promotional, evidence based and shaped by the Steering Committee, which has editorial control. In 2023, HPP co-hosted an event with the European Liver Patient’s Association (ELPA) in Brussels. The event brought together patient advocates, healthcare professionals and policy experts in the field of Wilson’s Disease, and rare diseases more broadly, to discuss what can be done at the EU level to drive change. It was funded by Alexion.Other activities
None declared
Meetings
Meetings
1 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
1 July 2024: We have noted that some meetings are appearing in duplicate, ie. some meetings seem to be listed twice. This seems to be because the Commission changes some element of a meeting data after the meeting has first been listed, which causes LobbyFacts to register it as a new meeting. We are investigating further.
-
Date 25 Oct 2023 Location Brussels, Belgium Subject Role of the EU in promoting heart health Cabinet Cabinet of Commissioner Mairead Mcguinness Portfolio Financial services, financial stability and Capital Markets Union Attending - Katherine Power (Cabinet member)